[Ip-health] Survey: US Health Agency Should Use Patent Rights To Keep Drugs Affordable
Michael H Davis
m.davis at csuohio.edu
Wed Sep 4 14:24:09 PDT 2013
How many decades ago was it that Peter Arno and I wrote, explaining fully this issue?
Prof. Michael H. Davis
Professor of Law
Cleveland State University
Cleveland, OH 44115
MY EMAIL ADDRESS IS ABOUT TO CHANGE. THE FOLLOWING WILL BE MY ONLY WORKING ADDRESS:
m.davis at csuohio.edu
Jamie Love <james.love at keionline.org> wrote:
Ronald Rader, since the 1990s, there is almost a news blackout on the
pricing of NIH funded drugs. I think our recent survey is the only thing I
have seen on the topic that involves polling.
On Wed, Sep 4, 2013 at 4:35 PM, Biotech. Info. Inst.
<biotech at biopharma.com>wrote:
> Most everyone reading this likely has strong opinions on the these topics.
> My questions, like the topic, concerned what is the state of U.S. general
> public knowledge and opinion.
> So, are there any recent survey, polling or other data concerning U.S.
> public (or health care professionals') knowledge and attitudes towards NIH
> pharmaceutical product-related patent licensing, related 'reasonable
> pricing' issues, etc.?" I vaguely recall there were some such data way
> back (in the early-mid 1990s?) when 'reasonable pricing' for
> pharmaceuticals resulting from NIH CRADAs was a hot topic.
> Thank you.
> Ronald A. Rader
> Biotechnology Information Institute
> 1700 Rockville Pike, Suite 400
> Rockville, MD 20852
> Phone: 301-424-0255
> E-mail: biotech at biopharma.com
> Web sites: www.biopharma.com; www.bioinfo.com
> On Sep 4, 2013, at 1:23 PM, Jamie Love <james.love at keionline.org> wrote:
> Ronald Rader,
> If the NIH funds the R&D for a new drug, it seems both unreasonable and
> appalling to me that US consumers would pay more for that drug than is
> charged in other high income countries. I personally don't think that
> extends to prices in lower income countries, where I hope that prices are
> lower. The Survey responses show that a very large proporiation of the
> public shares our view, as regards pricing of NIH funded drugs in high
> income countries.
> If the US imposes reference pricing oblgiations on NIH funded drugs, it
> would be easy to administer, and not require anything in particular as
> regards foreign prices, but it would protect US consumers from paying more,
> when they have already subdizied the development of the R&D, *AND* have
> rights in the patented inventions. I believe this set of facts applies
> to about 7 percent of FDA approved drugs, over the past five years, so it
> is not going to solve all problems as regards drug pricing, but it will
> impact one significant and important set of drugs.
> You can create all sorts of other policy questions to vet or survey, of
> course. But this is one that we are focusing on right now.
James Love. Knowledge Ecology International
http://www.keionline.org, KEI DC tel: +1.202.332.2670, US Mobile:
+1.202.361.3040, Geneva Mobile: +41.76.413.6584, twitter.com/jamie_love
Ip-health mailing list
Ip-health at lists.keionline.org
More information about the Ip-health